Summary
Cancer proteomics is a rapidly developing field and promises to accelerate the discovery of new diagnostic, prognostic and therapy-related biomarkers. Increasingly, the mechanisms of action of cancer drugs are defined at the molecular level. The possibility of detecting hundreds and thousands of proteins at the same point of time is a tool to define proteins associated with response or resistance to therapy. This strategy has been applied successfully in cell culture models and is implemented as translational research tool in early clinical trials of new anti-cancer agents. This review aims to summarize basic concepts and techniques of proteome analysis, its challenges and limitations, and discusses the opportunities for cancer therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adam B, Qu Y, Davis J, Ward M, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62: 3609–3614, 2002
Aebersold R, Goodlett D. Mass spectrometry in proteomics. Chem Rev, 101: 269–295, 2001
Borrebaeck C. Antibody microarray-based oncoproteomics. Expert Opin Biol Ther, 6: 833–838, 2006
Cayatte C, Pons C, Guigonis J, et al. Protein profiling of rat ventral prostate following chronic finasteride administration: identification and localization of a novel putative androgen-regulated protein. Mol Cell Proteomics, 5: 2031–2043, 2006
Cho W. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer, 6: 25, 2007
Corthals G, Aebersold R, Goodlett D. Identification of phosphorylation sites using microimmobilized metal affinity chromatography. Methods Enzymol, 405: 66–81, 2005
Cravatt B, Simon G, Yates Jr. The biological impact of mass-spectrometry-based proteomics. Nature, 450: 991–1000, 2007
Brown DPG, Gökmen-Polar Y, Jiang L, et al. A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells. Proteomics Clin Appl, 1: 18–31, 2007
Fitzpatrick DPG, You JS, Bemis KG, et al. Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method. Proteomics Clin Appl, 1: 246–263, 2007
Espina V, Wulfkuhle J, Calvert V, et al. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol, 383: 321–336, 2007
Friedman D, Lilley K. Optimizing the Difference Gel Electrophoresis (DIGE) technology. Methods Mol Biol, 428: 93–124, 2007
Goshe M. Characterizing phosphoproteins and phosphoproteomes using mass spectrometry. Brief Funct Genomic Proteomic, 4: 363–376, 2006
Görg A, Weiss W, Dunn M. Current two-dimensional electrophoresis technology for proteomics. Proteomics, 4: 3665–3685, 2004
Pollard HB, Srivastava M, Eidelmann O, et al. Protein microarray platforms for clinical proteomics. Proteomics Clin Appl, 1: 934–952, 2007
Hochstrasser D. Proteome in perspective. Clin Chem Lab Med, 36: 825–836, 1998
Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res, 10: 860–868, 2004
Korf U, Wiemann S. Protein microarrays as a discovery tool for studying protein–protein interactions. Expert Rev Proteomics, 2: 13–26, 2005
Loeffler-Ragg J, Skvortsov S, Sarg B, et al. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur J Cancer, 41: 2338–2346, 2005
McDonald T, Sheng S, Stanley B, et al. Expanding the subproteome of the inner mitochondria using protein separation technologies: one- and two-dimensional liquid chromatography and two-dimensional gel electrophoresis. Mol Cell Proteomics, 5: 2392–2411, 2006
Morandell S, Stasyk T, Grosstessner-Hain K, et al. Phosphoproteomics strategies for the functional analysis of signal transduction. Proteomics, 6: 4047–4056, 2006
Mustafa D, Kros J, Luider T. Combining laser capture microdissection and proteomics techniques. Methods Mol Biol, 428: 159–178, 2008
Negroni L, Samson M, Guigonis J, et al. Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90beta phosphorylation. Mol Cancer Ther, 6: 2747–2756, 2007
Nyman T. The role of mass spectrometry in proteome studies. Biomol Eng, 18: 221–227, 2001
Ornstein D, Rayford W, Fusaro V, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol, 172: 1302–1305, 2004
Petricoin ER, Ornstein D, Paweletz C, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst, 94: 1576–1578, 2002
Posadas E, Kwitkowski V, Kotz H, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer, 110: 309–317, 2007
Qu Y, Adam B, Yasui Y, Ward M, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem, 48: 1835–1843, 2002
Sanda T, Okamoto T, Uchida Y, et al. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia, 21: 2344–2353, 2007
Seibert V, Ebert M, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic, 4: 16–26, 2005
Skvortsov S, Sarg B, Loeffler-Ragg J, et al. Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol Cancer Ther, 3: 1551–1558, 2004
Skvortsov S, Skvortsova I, Sarg B, et al. Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Apoptosis, 10: 1175–1186, 2005
Smith F, Gallagher W, Fox E, et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg, 245: 259–266, 2007
Smith L, Welham K, Watson M, et al. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res, 16: 497–506, 2007
Sreekumar A, Nyati M, Varambally S, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res, 61: 7585–7593, 2001
Stasyk T, Huber L. Zooming in: fractionation strategies in proteomics. Proteomics, 4: 3704–3716, 2004
Venter J, Adams M, Myers E, et al. The sequence of the human genome. Science, 291: 1304–1351, 2001
Whiteley G. Proteomic patterns for cancer diagnosis-promise and challenges. Mol Biosys, 2: 358–363, 2006
Wingren C, Borrebaeck C. Progress in miniaturization of protein arrays – a step closer to high-density nanoarrays. Drug Discov Today, 12: 813–819, 2007
Yang Y, Zhang S, Howe K, et al. A comparison of nLC-ESI-MS/MS and nLC-MALDI-MS/MS for GeLC-based protein identification and iTRAQ-based shotgun quantitative proteomics. J Biomol Tech, 18: 226–237, 2007
Zhang Z, Bast RJ, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res, 64: 5882–5890, 2004
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loeffler-Ragg, J., Sarg, B., Mueller, D. et al. Proteomics, a new tool to monitor cancer therapy?. memo 1, 129–136 (2008). https://doi.org/10.1007/s12254-008-0048-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0048-8